



Friday, 6 February - 09:00 – 17:00

 HARVARD CLUB BOSTON, USA

# 2026

## EUFOREA Consensus Meeting on

### BIOLOGICS

WHICH BIOLOGIC FOR WHAT TYPE 2 AIRWAY CONDITION?

**Aim:** 1-day consensus meeting on which biologic for what respiratory condition: indications, considerations, and clinical follow-up.

#### Chairs:

- Prof Stella Lee (USA)
- Prof Benjamin Bleier (USA)
- Prof Kathleen Buchheit (USA)
- Prof Tanya Laidlaw (USA)

#### Experts:

- Prof Eugenio De Corso (Italy)
- Prof Wytse Fokkens (The Netherlands)
- Prof Philippe Gevaert (Belgium)
- Prof Joseph Han (USA)
- Prof Peter Hellings (Belgium)
- Prof Andrew Lane (USA)
- Prof Amber Luong (USA)
- Prof Mahboobeh Mahdavinia (USA)
- Prof Anju Peters (USA)
- Prof Klaus Rabe (Germany)
- Prof Murugappan Ramanathan (USA)
- Prof Rebecca Saff (USA)
- Prof Whitney Stevens (USA)
- Prof Justin Turner (USA)

#### Writers:

- Dr Gill Verstappen (Belgium)
- Dr Alan Workman (USA)

#### Observers:

- Mr Noah Braunstein
- Mrs Lieve Celis
- Mr Mark Corbett
- Mrs Mariana Guerreiro
- Mrs Megan Harden
- Mrs Khai Jing Ng
- Mr Asif Khan
- Mr Scott Nash
- Mrs Savannah Jane Scardo
- Mrs Katie Tassell
- Mrs Lakiea Wright

**External readers:** (TBC)



Friday, 6 February - 09:00 – 17:00

 HARVARD CLUB BOSTON, USA

# 2026

## EUFORA Consensus Meeting on

### **BIOLOGICS**

WHICH BIOLOGIC FOR WHAT TYPE 2 AIRWAY CONDITION?

**9:00 – 9:05**

#### **Welcome by the chairs**

*Prof Stella Lee, Prof Benjamin Bleier, Prof Kathleen Buchheit and Prof Tanya Laidlaw*

**9:05 – 9:15**

#### **Aims and outcomes of the consensus meeting**

*Prof Stella Lee and Prof Kathleen Buchheit*

From the morning session: Consensus on the top 3 most important things to move forward with:

- Biomarker development
- Emerging targets or pathways of interest
- Best outcomes for trials for CRSsNP

**9:15 – 10:00**

#### **Biomarkers for Endotyping & Precision Medicine**

*Prof Tanya Laidlaw*

- Biomarker development: Sampling location (tissue, mucous, blood, airway/breath), advantages and disadvantages of each
- Characterization of non-type 2 CRSwNP

**10:00 – 11:00**

#### **NOVEL THERAPEUTIC TARGETS and aiming for CURATIVE APPROACHES**

*Prof Stella Lee*

- Review existing pipelines and each target option

**11:00 – 11:15**

#### **Coffee Break**

**11:15 – 12:00**

#### **Best outcomes for CRSsNP trials**

*Prof Benjamin Bleier*

- Existing data, Phase 2 and Phase 3 trials, and best future approaches

**12:00 – 13:00**

#### **Open discussion and consensus**

*All Panel Members*

1. Biomarkers for Endotyping & Precision Medicine
2. Novel therapeutic targets
3. Best outcomes for CRSsNP trials



Friday, 6 February - 09:00 – 17:00

 HARVARD CLUB BOSTON, USA

# 2026

## EUFORA Consensus Meeting on

### **BIOLOGICS**

WHICH BIOLOGIC FOR WHAT TYPE 2 AIRWAY CONDITION?

**13:00 – 14:00** Lunch

**14:00 – 15:00** Discussion on the following aspects, which biologic for what respiratory condition for consensus

*Prof Kathleen Buchheit*

- Indication of biologics in asthma, COPD, and CRSwNP
- Indication of biologics in multimorbid patients
- Ideal timing of biologics

**15:00 – 15:30** Expert opinion on:

*All Panel Members*

- Tapering and switching
- Use of predictive biomarkers

**15:30 – 15:45** Coffee Break

**15:45 – 16:45** Biologics Pocket Guide update

*Prof Peter Hellings and Prof Wytske Fokkens*

**16:45 – 17:00** Summary and action plan

*Prof Tanya Laidlaw and Prof Benjamin Bleier*